全球新藥開發產業面對學名藥競爭壓力與創新缺口的挑戰:開發成本急遽上升，新藥成果卻逐年變少。越來越多公司發現合作的好處，這種新的組織方式終將打破傳統的研發流程，而成為創造財富的主要動力來源。根據 Chesbrough 在2003年提出的「開放式創新」，公司應該將研發流程的邊界模糊化，讓外界的創新進入公司的研發流程。開放式創新經營模式更進一步顯示:在生技產業中，讓各種創意流入企業 (Inbound Open Innovation)和讓各種創意流出企業 (Outbound Open Innovation)的必要性。本研究採取「演繹法中的三段論法」，先以開放式創新觀點切入醫藥產業，探討成功生技公司必須採取開放式創新以克服創新缺口。再個案研究T公司的「抗生素」--「奈諾沙星」在新藥開發過程亦有開放式創新，以推論個案公司是成功的生技公司。;The pharmaceutical industry faces intense pressure from generic competition and innovation deficit in the new drug development. The innovation cost increases rapidly but the result declines with years. More and more companies have found the benefits of collaboration. It will eventually break traditional development process, and be the main power source of wealth creation. Based on Chesbrough’s (2003) definition of open innovation, companies should blur the boundary of R&D and open up new channels for ideas coming from outside. Furthermore, the open innovation business model shows the necessity of letting ideas both flow out of (Outbound Open Innovation) and flow into (Inbound Open Innovation) the corporation in biotech industry. This study uses the method of Syllogism in Deduction. First, it discusses the need of successful companies to adopt open innovation to overcome the innovation deficit. Then, the company of the case study, Company T, also use open innovation when it developed Nemonoxacin. Finally, it is concluded that Company T is a successful biotechnology company.